Nanobiotix (NBTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $33.55 (-6.49%), Market cap $2.50B, 52-week low–high $3.64 ~ $55.07.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Financial statements, price targets, institutional (13F) holdings and related news for Nanobiotix are updated in real time on BlackAll Trade.
Nanobiotix trades at $33.55 (-6.49%). Real-time quotes and charts are available on BlackAll Trade.
Nanobiotix has a market cap of about $2.50B.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3